Adnan Alkhalili, MD
Medical Oncology · Perrysburg, OHNPI 1588648786
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $425 of the $488 with a category attached, or 87.2%. 9 manufacturers reported payments, led by Medtronic at 28.3% of the total. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.
Across 20 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$138
- Merck$118
- Novartis$66
- Johnson & Johnson$49
- Regeneron Healthcare Solutions, Inc.$34
- Amgen$31
- plus $52 from 3 others
Across 14 payments — averaging $10,505 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$112K
- Pfizer$36K
What the payments were for
- Food & beverage$42587%
- Education$6213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 1 | $138 |
| Merck | 4 | $118 |
| Novartis | 4 | $66 |
| Johnson & Johnson(2 entities) | 3 | $49 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Amgen | 2 | $31 |
| Pfizer | 2 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VISUALASE$138
How this compares
$488 in reported general payments places this provider in the 25th percentile of 157 medical oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 129 | $2,020,242 |
| ImbruvicaIbrutinib | 81 | $1,418,421 |
| Lenalidomide | 52 | $820,628 |
| XtandiEnzalutamide | 38 | $537,600 |
| PomalystPomalidomide | 20 | $461,444 |
| RevlimidLenalidomide | 12 | $252,587 |
| EliquisApixaban | 91 | $86,865 |
| CreonLipase/Protease/Amylase | 11 | $42,836 |
| Imatinib Mesylate | 17 | $23,313 |
| XareltoRivaroxaban | 15 | $12,687 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 338 | $11,660 |
| Anastrozole | 503 | $9,170 |
| Enoxaparin Sodium | 23 | $6,694 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,834 |
| Prochlorperazine Maleate | 111 | $3,639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $24 | $2,107,107220 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $15 | $461,44420 claims |
| Johnson & JohnsonXarelto | $49 | $12,68715 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 157 medical oncology providers in Ohio.
Other medical oncology in Perrysburg
- David CarboneColumbus$438K
- Elyse LowerCincinnati$312K
- Moshe OrnsteinCleveland$249K
- Christian RolfoColumbus$227K
- Timothy MooreColumbus$213K
- Maryam LustbergColumbus$176K
- Suneel KamathCleveland$120K
- Mark MarinellaKettering$84K
- Timothy BurnsColumbus$64K
- William TseCleveland$56K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.